Copper Influences the Antibacterial Outcomes of a β-Lactamase-Activated Prochelator against Drug-Resistant Bacteria

Jacqueline M. Zaengle-Barone, Abigail C. Jackson, David M. Besse, Bradford Becken, Mehreen Arshad, Patrick Casey Seed, Katherine J. Franz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The unabated rise in bacterial resistance to conventional antibiotics, coupled with collateral damage to normal flora incurred by overuse of broad-spectrum antibiotics, necessitates the development of new antimicrobials targeted against pathogenic organisms. Here, we explore the antibacterial outcomes and mode of action of a prochelator that exploits the production of β-lactamase enzymes by drug-resistant bacteria to convert a nontoxic compound into a metal-binding antimicrobial agent directly within the microenvironment of pathogenic organisms. Compound PcephPT (phenylacetamido-cephem-pyrithione) contains a cephalosporin core linked to 2-mercaptopyridine N-oxide (pyrithione) via one of its metal-chelating atoms, which minimizes its preactivation interaction with metal ions and its cytotoxicity. Spectroscopic and chromatographic assays indicate that PcephPT releases pyrithione in the presence of β-lactamase-producing bacteria. The prochelator shows enhanced antibacterial activity against strains expressing β-lactamases, with bactericidal efficacy improved by the presence of low-micromolar copper in the growth medium. Metal analysis shows that cell-associated copper accumulation by the prochelator is significantly lower than that induced by pyrithione itself, suggesting that the location of pyrithione release influences biological outcomes. Low-micromolar (4-8 μg/mL) minimum inhibitory concentration (MIC) values of PcephPT in ceftriaxone-resistant bacteria compared with median lethal dose (LD50) values greater than 250 μM in mammalian cells suggests favorable selectivity. Further investigation into the mechanisms of prochelators will provide insight for the design of new antibacterial agents that manipulate cellular metallobiology as a strategy against infection.

Original languageEnglish (US)
Pages (from-to)1019-1029
Number of pages11
JournalACS Infectious Diseases
Volume4
Issue number6
DOIs
StatePublished - Jun 8 2018

Fingerprint

Copper
Bacteria
Pharmaceutical Preparations
Metals
Anti-Bacterial Agents
Ceftriaxone
pyrithione
Lethal Dose 50
Microbial Sensitivity Tests
Cephalosporins
Anti-Infective Agents
Ions
Enzymes
Growth
Infection

Keywords

  • antibacterial
  • chelation
  • copper
  • prochelator
  • resistance
  • β-lactamase

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Zaengle-Barone, Jacqueline M. ; Jackson, Abigail C. ; Besse, David M. ; Becken, Bradford ; Arshad, Mehreen ; Seed, Patrick Casey ; Franz, Katherine J. / Copper Influences the Antibacterial Outcomes of a β-Lactamase-Activated Prochelator against Drug-Resistant Bacteria. In: ACS Infectious Diseases. 2018 ; Vol. 4, No. 6. pp. 1019-1029.
@article{33a38e2af0e9464a8f6e22e312259405,
title = "Copper Influences the Antibacterial Outcomes of a β-Lactamase-Activated Prochelator against Drug-Resistant Bacteria",
abstract = "The unabated rise in bacterial resistance to conventional antibiotics, coupled with collateral damage to normal flora incurred by overuse of broad-spectrum antibiotics, necessitates the development of new antimicrobials targeted against pathogenic organisms. Here, we explore the antibacterial outcomes and mode of action of a prochelator that exploits the production of β-lactamase enzymes by drug-resistant bacteria to convert a nontoxic compound into a metal-binding antimicrobial agent directly within the microenvironment of pathogenic organisms. Compound PcephPT (phenylacetamido-cephem-pyrithione) contains a cephalosporin core linked to 2-mercaptopyridine N-oxide (pyrithione) via one of its metal-chelating atoms, which minimizes its preactivation interaction with metal ions and its cytotoxicity. Spectroscopic and chromatographic assays indicate that PcephPT releases pyrithione in the presence of β-lactamase-producing bacteria. The prochelator shows enhanced antibacterial activity against strains expressing β-lactamases, with bactericidal efficacy improved by the presence of low-micromolar copper in the growth medium. Metal analysis shows that cell-associated copper accumulation by the prochelator is significantly lower than that induced by pyrithione itself, suggesting that the location of pyrithione release influences biological outcomes. Low-micromolar (4-8 μg/mL) minimum inhibitory concentration (MIC) values of PcephPT in ceftriaxone-resistant bacteria compared with median lethal dose (LD50) values greater than 250 μM in mammalian cells suggests favorable selectivity. Further investigation into the mechanisms of prochelators will provide insight for the design of new antibacterial agents that manipulate cellular metallobiology as a strategy against infection.",
keywords = "antibacterial, chelation, copper, prochelator, resistance, β-lactamase",
author = "Zaengle-Barone, {Jacqueline M.} and Jackson, {Abigail C.} and Besse, {David M.} and Bradford Becken and Mehreen Arshad and Seed, {Patrick Casey} and Franz, {Katherine J.}",
year = "2018",
month = "6",
day = "8",
doi = "10.1021/acsinfecdis.8b00037",
language = "English (US)",
volume = "4",
pages = "1019--1029",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",
number = "6",

}

Copper Influences the Antibacterial Outcomes of a β-Lactamase-Activated Prochelator against Drug-Resistant Bacteria. / Zaengle-Barone, Jacqueline M.; Jackson, Abigail C.; Besse, David M.; Becken, Bradford; Arshad, Mehreen; Seed, Patrick Casey; Franz, Katherine J.

In: ACS Infectious Diseases, Vol. 4, No. 6, 08.06.2018, p. 1019-1029.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Copper Influences the Antibacterial Outcomes of a β-Lactamase-Activated Prochelator against Drug-Resistant Bacteria

AU - Zaengle-Barone, Jacqueline M.

AU - Jackson, Abigail C.

AU - Besse, David M.

AU - Becken, Bradford

AU - Arshad, Mehreen

AU - Seed, Patrick Casey

AU - Franz, Katherine J.

PY - 2018/6/8

Y1 - 2018/6/8

N2 - The unabated rise in bacterial resistance to conventional antibiotics, coupled with collateral damage to normal flora incurred by overuse of broad-spectrum antibiotics, necessitates the development of new antimicrobials targeted against pathogenic organisms. Here, we explore the antibacterial outcomes and mode of action of a prochelator that exploits the production of β-lactamase enzymes by drug-resistant bacteria to convert a nontoxic compound into a metal-binding antimicrobial agent directly within the microenvironment of pathogenic organisms. Compound PcephPT (phenylacetamido-cephem-pyrithione) contains a cephalosporin core linked to 2-mercaptopyridine N-oxide (pyrithione) via one of its metal-chelating atoms, which minimizes its preactivation interaction with metal ions and its cytotoxicity. Spectroscopic and chromatographic assays indicate that PcephPT releases pyrithione in the presence of β-lactamase-producing bacteria. The prochelator shows enhanced antibacterial activity against strains expressing β-lactamases, with bactericidal efficacy improved by the presence of low-micromolar copper in the growth medium. Metal analysis shows that cell-associated copper accumulation by the prochelator is significantly lower than that induced by pyrithione itself, suggesting that the location of pyrithione release influences biological outcomes. Low-micromolar (4-8 μg/mL) minimum inhibitory concentration (MIC) values of PcephPT in ceftriaxone-resistant bacteria compared with median lethal dose (LD50) values greater than 250 μM in mammalian cells suggests favorable selectivity. Further investigation into the mechanisms of prochelators will provide insight for the design of new antibacterial agents that manipulate cellular metallobiology as a strategy against infection.

AB - The unabated rise in bacterial resistance to conventional antibiotics, coupled with collateral damage to normal flora incurred by overuse of broad-spectrum antibiotics, necessitates the development of new antimicrobials targeted against pathogenic organisms. Here, we explore the antibacterial outcomes and mode of action of a prochelator that exploits the production of β-lactamase enzymes by drug-resistant bacteria to convert a nontoxic compound into a metal-binding antimicrobial agent directly within the microenvironment of pathogenic organisms. Compound PcephPT (phenylacetamido-cephem-pyrithione) contains a cephalosporin core linked to 2-mercaptopyridine N-oxide (pyrithione) via one of its metal-chelating atoms, which minimizes its preactivation interaction with metal ions and its cytotoxicity. Spectroscopic and chromatographic assays indicate that PcephPT releases pyrithione in the presence of β-lactamase-producing bacteria. The prochelator shows enhanced antibacterial activity against strains expressing β-lactamases, with bactericidal efficacy improved by the presence of low-micromolar copper in the growth medium. Metal analysis shows that cell-associated copper accumulation by the prochelator is significantly lower than that induced by pyrithione itself, suggesting that the location of pyrithione release influences biological outcomes. Low-micromolar (4-8 μg/mL) minimum inhibitory concentration (MIC) values of PcephPT in ceftriaxone-resistant bacteria compared with median lethal dose (LD50) values greater than 250 μM in mammalian cells suggests favorable selectivity. Further investigation into the mechanisms of prochelators will provide insight for the design of new antibacterial agents that manipulate cellular metallobiology as a strategy against infection.

KW - antibacterial

KW - chelation

KW - copper

KW - prochelator

KW - resistance

KW - β-lactamase

UR - http://www.scopus.com/inward/record.url?scp=85048301485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048301485&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.8b00037

DO - 10.1021/acsinfecdis.8b00037

M3 - Article

VL - 4

SP - 1019

EP - 1029

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

IS - 6

ER -